Alan Leong

My Bio at

[Alan Leong @alanhobbes]

#BioWatch's commentary on $CAPR #Capricor - #NipponShinyaku license expansion for #Duchenne #DMD. Read at: https://t.co/cHLy2uQn9Q

[Alan Leong @alanhobbes]

#BioWatch update on #Capricor $CAPR concerning positive 18-month OLE results of #CAP1002 to treat #Duchenne #DMD. Read at: https://t.co/cS7PEpH5Og

[Alan Leong @alanhobbes]

#BioWatch's commentary on #Capricor's $CAPR Q3-2022 Update. Read at: https://t.co/qMSHnVzwHt

[Alan Leong @alanhobbes]

#BioWatch News Commentary on #Corcept's $CORT Q3-2022 Update & Guidance. Read at: https://t.co/3AM3kgTjPX

[Alan Leong @alanhobbes]

#BioWatchNews special update on #Capricor $CAPR. Read at: https://t.co/dhM0QOSZFR

[Alan Leong @alanhobbes]

#Capricor Therapeutics' $CAPR Q2-2022 Update - #BioWatch's commentary at: https://t.co/KN3h2cmRdv

[Alan Leong @alanhobbes]

#BioWatch Update - #Corcept $CORT - Q2-2022 - Trio of Clinical Results Coming. Read at: https://t.co/Gzt4WEay23

[Alan Leong @alanhobbes]

#Corcept Therapeutics $CORT - Special #BioWatch Update - Psychiatric & Neurological Indications - Read at https://t.co/qgvg2Q0VoC

[Alan Leong @alanhobbes]

BioWatch Commentary: Capricor Therapeutics - Conference Call - One Year Extension Results - DMD - Read at: https://t.co/1MzfCFljDe

[Alan Leong @alanhobbes]

Check out my latest article: Capricor DMD Extension Results - Conference Call: O-LE! O-LE! https://t.co/7CAZh9pF33 via @LinkedIn

[Alan Leong @alanhobbes]

#BioWatch #Capricor Therapeutics $CAPR - Extension Data Builds Case - #Duchenne Muscular Dystrophy - Read at: https://t.co/BIeuaPsR0i

[Alan Leong @alanhobbes]

#BioWatch News' commentary on #Corcept's $CORT updated ovarian cancer results & pivotal trial design. Plus an added bonus: major Phase 2 ALS trial design. Read at: https://t.co/GEXJJMHzcx

[Alan Leong @alanhobbes]

BioWatch News' May 2022 Updates on #Corcept Therapeutics $CORT (https://t.co/W6u2m3LGrP) and #Capricor Therapeutics $CAPR (https://t.co/rek7z8yCPF). Enjoy!

[Alan Leong @alanhobbes]

#BioWatch takes a 2nd look - Corcept's ovarian cancer results - The Median is not the Message. Read at: https://t.co/YVBuCGXV2S

[Alan Leong @alanhobbes]

#BioWatch commentary on #Corcept's $CORT ovarian cancer results and program update. Read at: https://t.co/pa6RRn84h4

[Alan Leong @alanhobbes]

#BioWatch commentary on #Capricor's $CORT Q4 & FY 2021 results. Read at https://t.co/PaL8KKwjGO

[Alan Leong @alanhobbes]

#BioWatch News commentary on #Corcept's $CORT Q4-2021 / FY2021 Update. Read at https://t.co/5Kme5kzBpQ

[Alan Leong @alanhobbes]

BioWatch Update on #Capricor Therapeutics $CAPR including thots on recent licensing agreement. Read at: https://t.co/EfaVnr0HDz

[Alan Leong @alanhobbes]

#BioWatch update on #Capricor $CAPR on its #HOPE-3 Trial + more. Read at: https://t.co/AkHdBMCZ1U

[Alan Leong @alanhobbes]

Congratulations to #Immusoft on its $4M grant from #CIRM, and congrats to its co-founder & inventor: Matt Scholz: https://t.co/swboZOD0Oy